【作者】 邢时云；

【导师】 杨卫兵；

【作者基本信息】 遵义医学院 ， 内科学， 2011， 硕士

【摘要】 目的：探讨联合检测晚期肺癌患者外周血血管内皮生长因子(vascular endothelial growth factor, VEGF)和金属硫蛋白(Metallothionein, MT)与肺癌病理类型、淋巴结转移情况、疗效、预后判断之间的关系。方法：实验分为肺癌组(33例晚期肺癌患者)和对照组(30例健康者)；采用双抗体夹心(ABC-ELISA)法测定两组血清VEGF和MT的含量；实时定量逆转录聚合酶链反应(RT-PCR)法检测两组外周血单个核细胞VEGF mRNA和MT mRNA的表达情况。结果：对照组血清VEGF、MT含量分别为(174.3±60.1) pg/ml、(5.7±2.8) ng/ml,肺癌组患者化疗前VEGF、MT含量分别为(401.2±142.4) pg/ml、(13.9±6.0) ng/ml,肺癌组患者化疗前血清VEGF及MT均明显高于对照组(P<0.01)。对照组外周血VEGF mRNA、MT mRNA的表达分别为(48.8±24.1)、(95.0±30.3),肺癌组患者化疗前外周血VEGF mRNA、MT mRNA分别为(209.6±90.3)、(184.2±103.2),肺癌组患者化疗前外周血VEGF mRNA、MT mRNA的表达均明显高于对照组(P<0.01)。肺癌组患者化疗后VEGF蛋白水平低于化疗前(P<0.05),而外周血VEGF mRNA化疗前后无差异性(P>0.05)；外周血MT蛋白及mRNA治疗前后亦无差异性(P>0.05)。VEGF与MT的蛋白及基因水平表达与晚期肺癌患者性别、病理类型、淋巴结有无转移及疗效均无相关性,差异无统计学意义(P>0.05)。肺癌组VEGF及MT阳性率分别为78.8%及63.6%,两种肿瘤标志物联合检测阳性率上升为91%。血清VEGF与MT测定值之间无相关性。结论：血清VEGF与MT联合检测可提高阳性率,但二者之间无相关性。VEGF、MT联合检测与晚期肺癌患者性别、病理类型、淋巴结有无转移、疗效及预后均无相关性。更多还原

【Abstract】 Objective:To investigate the relationship between the combined detection of Peripheral Blood vascular endothelial growth factor (VEGF), metallothionein(MT) and pathological type, lymph node metastasis, efficacy and prognosis and other factors in Patients with advanced lung cancer. Methods:The study were divided into lung cancer group (33 patients with advanced lung cancer patients) and control group (30 healthy people).The serum VEGF and MT levels were measured by ABC-ELISA double antibody sandwich method in the two groups. Peripheral blood mononuclear cells expression of VEGF mRNA and MT mRNA were measured by Reverse transcription polymerase chain reaction (RT-PCR). Results:Serum VEGF and MT normal expression level were (174.3±60.1) pg/ml and (5.7±2.8) ng/ml, VEGF and MT expression level in Lung cancer patients before treatment were (401.2±142.4) pg/ml and (13.9±6.0) ng/ml, Serum VEGF and MT expression level in patients with lung cancers before chemotherapy were significantly higher than normal group (P<0.01). Peripheral blood VEGF mRNA and MT mRNA in normal group were (48.8±24.1) and (95.0±30.3) VEGF mRNA and MT mRNA in Lung cancer patients before chemotherapy expression level were (209.6±90.3) and (184.2±103.2), MT mRNA and VEGF mRNA in Lung cancer patients before chemotherapy was significantly higher than normal group. Serum VEGF levels in lung cancer patients after chemotherapy were Less than the before (P <0.05). However, VEGF mRNA in Peripheral Blood before and after the chemotherapy of advanced lung cancer have no difference (P> 0.05); MT protein and mRNA in peripheral blood before and after the chemotherapy of advanced lung cancer have no differences (P> 0.05).VEGF and MT have no correlation with gender, pathological type, lymph node metastasis and efficacy, the differences have not statistically significant (P> 0.05).The positive rates of VEGF and MT in lung cancer patients were 78.8% and 63.6%.There were no correlation between the measured value of serum VEGF and MT. Conclusion: Combined detection of serum VEGF and MT can improve the positive rate, while there were no correlation between the two indexes. VEGF and MT have no correlation with gender, pathological type, lymph node metastasis , efficacy and prognosis in advanced lung cancer.更多还原